RxDoctor Payments DataLook up a doctor →

Nirat Beohar, MD

Interventional Cardiology · Miami Beach, FLNPI 1558337329

Payments from drug & device makers

$271,434in general payments, 2019–2025

Across 964 payments — averaging $281.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$147K
  • Medtronic$44K
  • Abbott$33K
  • Cardiovascular Systems Inc.$32K
  • Cordis US CORP.$9K
  • Boston Scientific$3K
  • plus $4K from 14 others

What the payments were for

  • Consulting fees$26,67535%
  • Speaking & faculty fees$23,85032%
  • Travel & lodging$7,20210%
  • Food & beverage$17,47423%
  • Education$880%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$271,434 in reported general payments places this provider in the 90th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$138,481
Medicare patients
209
Services billed
680

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab11$16,117
EliquisApixaban17$15,521
EntrestoSacubitril/Valsartan15$14,415
Metoprolol Succinate58$649
Ezetimibe25$602
Rosuvastatin Calcium81$565
Atorvastatin Calcium94$505
ClopidogrelClopidogrel Bisulfate92$363
Bumetanide18$246
Carvedilol42$111
Amlodipine Besylate13$94
Furosemide24$60
Pravastatin Sodium13$55
Losartan Potassium12$48
Lisinopril19$38

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$51$15,52117 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Miami Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →